CUTISS closes CHF 56M Series C round and signs agreement with leading European burn center

Switzerland, 10 September 2025 – CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M. The proceeds will be used to progress with the Phase 3 trial of the lead product denovoSkin™, which started earlier this year, and to prepare for its commercialization. The funds will also advance the industrialization and clinical readiness of the world’s first automated manufacturing platform for persona